Temmler Werke Holding Gmbh

Primary objective: To describe the safety and tolerability of isavuconazole by observing treatment-emergent adverse events (TEAEs). Secondary objectives: To describe the efficacy of isavuconazole in the treatment of invasive fungal disease (IFD) caused by Aspergillus and other filamentous fungi in Chinese patients. To observe other safety and tolerability characteristics of isavuconazole. To evaluate the pharmacokinetics of isavuconazole in the treatment of IFD caused by Aspergillus and other filamentous fungi in Chinese patients.

Healthy subjects were given a single dose of diclofenac sodium enteric-coated capsules (test preparation) and diclofenac sodium enteric-coated tablets (trade name: Voltaren) on an empty stomach or after a meal. The concentration of diclofenac in plasma was determined to study the absorption rate and extent of the test preparation and the reference preparation, to evaluate whether the test preparation and the reference preparation were bioequivalent, and to compare the effect of diet on the pharmacokinetics of the test preparation and the reference preparation.